SELLAS Life Sciences Group, Inc. is a late-stage biopharmaceutical company dedicated to the development of innovative cancer immunotherapies addressing various cancer types in the United States. The company recorded an operating income of -$31,513,000.00 reflecting its earnings from core operations. Furthermore, the operating expenses amount to $31,513,000.00 encompassing various operational costs incurred during the fiscal year $2024. A key indicator of the company's operational profitability, the EBITDA is -$30,881,000.00. This financial data is significant as it provides insights into the company's performance. Additionally, the weighted average number of diluted shares outstanding is $612,024,000.00 which reflects potential dilution effects that may impact shareholders. The lead product candidate, galinpepimut-S (GPS), is currently being evaluated in Phase III clinical trials for acute myeloid leukemia and in Phase 1/2 clinical trials for ovarian cancer. Furthermore, the company develops nelipepimut-S, an immunotherapy targeting human epidermal growth factor receptor 2, presently in Phase 2b clinical trials for early-stage breast cancer. In collaboration with Merck & Co., Inc., SELLAS is assessing GPS alongside the PD1 blocker pembrolizumab in a Phase 1/2 clinical trial across up to five cancer indications, including both hematologic malignancies and solid tumors. Founded in 2012, the company has established its headquarters in New York, New York. The stock is affordable at $1.90 making it suitable for budget-conscious investors. Investors should note that the stock has an average trading volume of 2,865,754.00 indicating moderate liquidity within the market. With a market capitalization of $183,590,600.00 the company is classified as a small-cap player, offering potential growth opportunities. SELLAS Life Sciences Group, Inc. is a key player in the Biotechnology industry, contributing significantly to the overall market landscape. Moreover, it belongs to the Healthcare sector, driving innovation and growth in the biopharmaceutical field. Investors and market analysts alike may find the company’s strategic direction and collaborations to be notable drivers of its future success.